ILLUMINA, INC. (ILMN)
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Open ILLUMINA, INC. in the interactive graph- Ticker
- ILMN
- SEC CIK
- 0001110803
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Periods
- FY2025 Q1, FY2026, FY2026 Q1, FY2026 Q3, FY2027
- Headquarters
- San Diego, CA
- Employees
- 8,600
Key figures
- Revenue 1.09B USD
- NetIncome 134.00M USD
- DilutedEPS 1.15 USD/share
Reported figures
- BasicEPS 0.83 USD/share
- BasicEPS 0.88 USD/share
- BasicSharesOutstanding 153.00M count
- BasicSharesOutstanding 159.00M count
- CapitalExpenditure 32.00M USD
- CapitalExpenditure 38.00M USD
- CostOfRevenue 358.00M USD
- CostOfRevenue 370.00M USD
- DilutedEPS 0.82 USD/share
- DilutedEPS 0.87 USD/share
- DilutedEPS 0.97 USD/share
- DilutedEPS 1.15 USD/share
- FreeCashFlow 208.00M USD
- FreeCashFlow 251.00M USD
- GrossMargin 65.6 percent
- GrossMargin 66.1 percent
- GrossMargin 67.4 percent
- GrossMargin 68.2 percent
- GrossProfit 683.00M USD
- GrossProfit 702.00M USD
- GrossProfit 721.00M USD
- GrossProfit 744.00M USD
- InterestExpense 24.00M USD
- NetIncome 131.00M USD
- NetIncome 134.00M USD
- OperatingCashFlow 240.00M USD
- OperatingCashFlow 289.00M USD
- OperatingExpenses 512.00M USD
- OperatingExpenses 519.00M USD
- OperatingIncome 164.00M USD
- OperatingIncome 209.00M USD
- OperatingIncome 212.00M USD
- OperatingIncome 239.00M USD
- OperatingMargin 15.8 percent
- OperatingMargin 19.2 percent
- OperatingMargin 20.4 percent
- OperatingMargin 21.9 percent
- OtherMetric 1.2 percent
- OtherMetric 3.5 percent
- OtherMetric 69.00M USD
- and 12 more in the interactive graph
Guidance
- DilutedEPS guidance 5.15–5.30 USD/share
- OperatingMargin guidance 23.4–23.6 percent
- Revenue guidance 4.52B–4.62B USD
Drivers
- Increasing demand for NovaSeq X as clinical customers expand into new application areas
- Strength of the Illumina ecosystem and progress against strategy contributed to strong Q1
Risks
- Ability to adjust operating expenses to align with revenue expectations
- Challenges inherent in developing, manufacturing, and launching new products and services,
- Changes in the rate of growth in the markets we serve, including the proteomics market
- Impact of recently launched or pre-announced products and services on existing products an
- Risk of additional litigation arising in connection with the GRAIL acquisition
- Success of products and services competitive with our own
- Uncertainty or adverse economic and business conditions, including as a result of slowing
- Uncertainty regarding tariffs imposed or threatened by the U.S. government and its trading
- Uncertainty regarding the impact of inclusion on the unreliable entities list by regulator
- Volume, timing and mix of customer orders among products and services
Corporate events
- Board of Directors authorized an additional $1.5 billion in share repurchases on April 28,